Evidence map›Paper›PMID 26449721›Full record

Trial reportPsychopharmacology2016

Amphetamine increases activity but not exploration in humans and mice.

Arpi Minassian, Jared W Young, Zackary A Cope, Brook L Henry, Mark A Geyer, William Perry

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Psychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Amphetamine Modestly Improves Conners' Continuous Performance Test Performance in Healthy Adults.Journal of the International Neuropsychological Society : JINS · 2018
    Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Mapping the landscape of social behavior.bioRxiv : the preprint server for biology · 2024
    Article
  12. Review
  13. Article
  14. Sensational site: the sodium pump ouabain-binding site and its ligands.American journal of physiology. Cell physiology · 2024
    Review
  15. Article
  16. Article
  17. A novel murine model of mania.Molecular psychiatry · 2023
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Arpi MinassianDepartment of Psychiatry, University of California San Diego, 200 West Arbor Drive, La Jolla, Mailcode 8620, San Diego, CA, 92103-8620, USA. aminassian@ucsd.edu.
Jared W YoungDepartment of Psychiatry, University of California San Diego, 200 West Arbor Drive, La Jolla, Mailcode 8620, San Diego, CA, 92103-8620, USA.
Zackary A CopeDepartment of Psychiatry, University of California San Diego, 200 West Arbor Drive, La Jolla, Mailcode 8620, San Diego, CA, 92103-8620, USA.
Brook L HenryDepartment of Psychiatry, University of California San Diego, 200 West Arbor Drive, La Jolla, Mailcode 8620, San Diego, CA, 92103-8620, USA.
Mark A GeyerDepartment of Psychiatry, University of California San Diego, 200 West Arbor Drive, La Jolla, Mailcode 8620, San Diego, CA, 92103-8620, USA.
William PerryDepartment of Psychiatry, University of California San Diego, 200 West Arbor Drive, La Jolla, Mailcode 8620, San Diego, CA, 92103-8620, USA.
University of California, San Diego · USVA San Diego Healthcare System · US

Funding

STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer E Iudicello · 2001 to 2026
$50.4M
Translational Methamphetamine AIDS Research Center (TMARC)P50DA026306 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GRANT, IGOR · 2009 to 2018
$33.9M
Fellowship on Biological Psychiatry and NeuroscienceT32MH018399 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Pei-an (Betty) Shih · 1986 to 2026
$7.3M
Inhibitory Deficits in Mania and Hyperdopaminiergic MiceR01MH071916 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GEYER, MARK A, PERRY, WILLIAM · 2004 to 2014
$4.2M
NIDA NIH HHS P50 DA026306NIMH NIH HHS P30 MH062512NIMH NIH HHS R01 MH071916NIMH NIH HHS T32 MH018399
6 · The paper itself

Abstract

rationaleCross-species quantification of physiological behavior enables a better understanding of the biological systems underlying neuropsychiatric diseases such as bipolar disorder (BD). Cardinal symptoms of manic BD include increased motor activity and goal-directed behavior, thought to be related to increased catecholamine activity, potentially selective to dopamine homeostatic dysregulation.

objectivesThe objective of this study was to test whether acute administration of amphetamine, a norepinephrine/dopamine transporter inhibitor and dopamine releaser, would replicate the profile of activity and exploration observed in both humans with manic BD and mouse models of mania.

methodsHealthy volunteers with no psychiatric history were randomized to a one-time dose of placebo (n = 25), 10 mg d-amphetamine (n = 18), or 20 mg amphetamine (n = 23). Eighty mice were administered one of four doses of d-amphetamine or vehicle. Humans and mice were tested in the behavioral pattern monitor (BPM), which quantifies motor activity, exploratory behavior, and spatial patterns of behavior.

resultsIn humans, the 20-mg dose of amphetamine increased motor activity as measured by acceleration without marked effects on exploration or spatial patterns of activity. In mice, amphetamine increased activity, decreased specific exploration, and caused straighter, one-dimensional movements in a dose-dependent manner.

conclusionsConsistent with mice, amphetamine increased motoric activity in humans without increasing exploration. Given that BD patients exhibit heightened exploration, these data further emphasize the limitation of amphetamine-induced hyperactivity as a suitable model for BD. Further, these studies highlight the utility of cross-species physiological paradigms in validating biological mechanisms of psychiatric diseases.

Indexed as

AdolescentAdrenergic Uptake InhibitorsAdultAnimalsBipolar DisorderCatecholaminesCentral Nervous System StimulantsDextroamphetamineDopamineDopamine Uptake InhibitorsDose-Response Relationship, DrugExploratory BehaviorFemaleGoalsHumansMaleAdrenergic Uptake InhibitorsCatecholaminesCentral Nervous System StimulantsDextroamphetamineDopamineDopamine Uptake InhibitorsAmphetamineBipolar disorderCatecholaminesDopamineExplorationManiaMotor activity

Identifiers

PMID26449721
PMCPMC4703551
OpenAlexW2178587561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.